Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 11/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25585024 | 0.80 | CYP19A1 (0.49) | GRM5GRM4CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL25878873 | 0.80 | RIPK1 (0.55) | GRM5RIPK1 | |
| SCHEMBL26497736 | 0.78 | BACE1 (0.41) | RIPK1 | |
| SCHEMBL23075141 | 0.76 | RIPK1 (0.47) | RIPK1 | |
| SCHEMBL26497603 | 0.74 | RIPK1 (0.39) | RIPK1 | |
| SCHEMBL25586729 | 0.72 | RIPK1 (0.56) | GRM5RIPK1 | |
| SCHEMBL15964555 | 0.71 | SRD5A1 (0.40) | RIPK1CYP3A4 | |
| SCHEMBL31656001 | 0.71 | SRD5A1 (0.40) | RIPK1CYP3A4 | |
| SCHEMBL15964550 | 0.71 | AADAT (0.50) | — | |
| SCHEMBL15964551 | 0.71 | TSHR (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167129-A1 | HETEROCYCLIC AMIDE FOR INHIBITING RIP1 KINASE AND USES THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167129-A1 | HETEROCYCLIC AMIDE FOR INHIBITING RIP1 KINASE AND USES THEREOF | RIPK1, RIPK3, RIPK4 | GRM5 3049/4885RIPK1 1/4885GRM4 3455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.